Axsome Therapeutics has initiated the FORWARD Phase III trial evaluating AXS-14 for the management of fibromyalgia, with the ...
Intellia Therapeutics CEO John Leonard explained the circumstances of the patient death at the J.P. Morgan Healthcare ...
The FDA and EMA's joint guidance was created to ensure the pharmaceutical industry employs best practices when using AI in ...
Sanofi's amlitelimab has shown promise in the Phase III COAST 1 trial, but data from the COAST 2 study is yet to be announced ...
In a paper published in Nature Scientific Reports, the UK Biobank was used to better understand how the risk of stroke is ...
The UK has announced new clinical trial regulatory reforms to boost its appeal as a leading destination for medical research.
An independent data monitoring committee has advised Akeso to submit a sNDA to the NMPA for cadonilimab’s approval in gastric ...
Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...
MRM Health has received clearance from the FDA for its IND application, enabling the company to start the STARFISH-UC Phase ...
BioAge’s NLRP3 inhibitor has shown potential to reduce high-sensitivity C-reactive protein (hsCRP), a key marker of ...
Johnson & Johnson’s (J&J) Caplyta (lumateperone) plus antidepressants nearly doubled the likelihood of remission after six weeks, with benefit remaining for more than six months in patients with major ...
Ocugen’s AAV gene therapy, OCU410, has demonstrated its capacity to reduce geographic atrophy (GA)-associated lesion growth in the Phase II ArMaDa trial. Image credit: VectorsMarket via ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback